

	Group 1 <i>n</i> = 55	Group 2 <i>n</i> = 51	<i>p</i>-Value
Tumour size, mean \pm standard deviation (SD), mm	2.90 \pm 1.43	3.55 \pm 1.37	0.030
T stage, <i>n</i>, %			0.131
Ta	41 (74.5%)	31 (60.8%)	
T1	14 (25.5%)	20 (39.2%)	
Grade, <i>n</i>, %			0.057
Low grade	40 (72.7%)	28 (54.9%)	
High grade	15 (27.3%)	23 (45.1%)	
Muscle tissue sampling			0.010
Absent	15 (27.3%)	4 (7.8%)	
Present	40 (70.2%)	47 (92.2%)	
Resection			0.021
Incomplete	10 (18.2%)	2 (3.9%)	
Complete	45 (81.8%)	49 (96.1%)	
Obturator reflex			0.003
Absent	38 (69.1%)	47 (92.2%)	
Present	17 (30.9%)	4 (7.8%)	
Recurrence, <i>n</i>, %			0.010
Absent	30 (54.5%)	40 (78.4%)	
Present	25 (45.5%)	11 (21.6%)	
Progression, <i>n</i>, %			0.106
Absent	47 (85.5%)	49 (96.1%)	
Present	8 (14.5%)	2 (3.9%)	
Time to recurrence, mean \pm SD, month	4.44 \pm 6.02	7.76 \pm 15.66	0.097
Complication, <i>n</i>, %			0.117
Haematuria	5 (9.1%)	1 (2.0%)	
Cystitis	5 (9.1%)	5 (9.8%)	
Bladder perforation	3 (5.5%)	0	

Table 2 Comparison of group oncological outcomes.